Drug for adults with NF1 and non-surgically treatable nerve tumors
Part of Brain & nervous system, Cancer, Genetic & congenital clinical trials.
This Phase 2 trial tests HL-085 in adults with neurofibromatosis type 1 (NF1) who have a nerve tumor (plexiform neurofibroma) that cannot be removed by surgery and causes symptoms. It aims to shrink or control the tumor by measuring changes on MRI and monitoring side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re at least 18 years old when the study starts.
- You have NF1 and a plexiform neurofibroma that cannot be removed by surgery and is causing symptoms.
- You have an NF1 diagnosis by genetic mutation or by meeting at least one NF1 sign (like many café-au-lait spots, certain eye findings, specific bone changes, or an NF1 first-degree relative).
- You have a measurable plexiform neurofibroma lesion (at least 3 cm) that can be checked with MRI.
- You can do study visits and follow-up, and your general functioning is good (ECOG 0 to 2).
- You can swallow and take pills by mouth, and you can safely have MRI scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether the drug selumetinib can prevent the growth of plexiform neurofibromas (nerve tumors) in young children with NF1. Children are first monitored with MRI scans, and if a tumor appears or grows, they may receive treatment.
This trial tests a combination of two targeted drugs (cabozantinib and selumetinib) for people with NF1 who have plexiform neurofibromas that are growing or causing significant problems. The goal is to see if this combination can shrink or slow the growth of these tumors.
This study is looking for adults with NF1 who have had a plexiform neurofibroma. It aims to find better ways to detect tumors early, which could help with treatment decisions.
This trial tests a capsule medication (smetinib) for people with type 1 neurofibromatosis (NF1) who have tumors that can be surgically removed but have not spread to vital areas like the brain or spine. The goal is to see if the drug can help shrink or control these tumors.
This trial tests a new pill (smeitinib) to shrink tumors caused by neurofibromatosis type 1 (NF1). It is for adults with NF1 who have tumors that cannot be removed by surgery, including those that press on the brain or spine.
This study monitors people with neurofibromatosis type 1 (NF1) over time to watch for signs that their nerve tumors might turn into cancer. It helps researchers learn which tumors are more likely to change and may lead to better care.
Hear when a new Neurofibromatosis 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.